Reinventing the antimicrobial pipeline in response to the global crisis of antimicrobial-resistant infections [version 1; peer review: 2 approved]
The pipeline for new antibiotics is dry. Despite the creation of public/private initiatives like Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (Carb-X) and the Antimicrobial Resistance (AMR) Centre, the current focus on ‘push-pull’ incentives for the pharmaceutical industry s...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
F1000 Research Ltd
2019-03-01
|
| Series: | F1000Research |
| Online Access: | https://f1000research.com/articles/8-238/v1 |
| _version_ | 1828516138946920448 |
|---|---|
| author | Andrew C. Singer Claas Kirchhelle Adam P. Roberts |
| author_facet | Andrew C. Singer Claas Kirchhelle Adam P. Roberts |
| author_sort | Andrew C. Singer |
| collection | DOAJ |
| description | The pipeline for new antibiotics is dry. Despite the creation of public/private initiatives like Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (Carb-X) and the Antimicrobial Resistance (AMR) Centre, the current focus on ‘push-pull’ incentives for the pharmaceutical industry still relies on economic return. We propose a joint, internationally-funded antimicrobial development institute that would fund permanent staff to take on roles previously assigned to pharmaceutical companies. This institute would receive ring-fenced, long-term, core funding from participating countries as well as charities, with the aim to focus on transforming the largely dormant antimicrobial pipeline. Resulting drugs would be sold globally and according to a principle of shared burdens. Our proposed model for antimicrobial development aims to maximise society’s investment, through open science, investment in people, and the sharing of intellectual property. |
| first_indexed | 2024-12-11T18:22:49Z |
| format | Article |
| id | doaj.art-d30d1704f15240eb9382f86483c9099f |
| institution | Directory Open Access Journal |
| issn | 2046-1402 |
| language | English |
| last_indexed | 2024-12-11T18:22:49Z |
| publishDate | 2019-03-01 |
| publisher | F1000 Research Ltd |
| record_format | Article |
| series | F1000Research |
| spelling | doaj.art-d30d1704f15240eb9382f86483c9099f2022-12-22T00:55:11ZengF1000 Research LtdF1000Research2046-14022019-03-01810.12688/f1000research.18302.120020Reinventing the antimicrobial pipeline in response to the global crisis of antimicrobial-resistant infections [version 1; peer review: 2 approved]Andrew C. Singer0Claas Kirchhelle1Adam P. Roberts2NERC Centre for Ecology & Hydrology, Wallingford, OX10 8BB, UKWellcome Unit for the History of Medicine, University of Oxford, Oxford, OX2 6PE, UKAntimicrobial Chemotherapy and Resistance, Liverpool School of Tropical Medicine, Liverpool, L3 5QA, UKThe pipeline for new antibiotics is dry. Despite the creation of public/private initiatives like Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (Carb-X) and the Antimicrobial Resistance (AMR) Centre, the current focus on ‘push-pull’ incentives for the pharmaceutical industry still relies on economic return. We propose a joint, internationally-funded antimicrobial development institute that would fund permanent staff to take on roles previously assigned to pharmaceutical companies. This institute would receive ring-fenced, long-term, core funding from participating countries as well as charities, with the aim to focus on transforming the largely dormant antimicrobial pipeline. Resulting drugs would be sold globally and according to a principle of shared burdens. Our proposed model for antimicrobial development aims to maximise society’s investment, through open science, investment in people, and the sharing of intellectual property.https://f1000research.com/articles/8-238/v1 |
| spellingShingle | Andrew C. Singer Claas Kirchhelle Adam P. Roberts Reinventing the antimicrobial pipeline in response to the global crisis of antimicrobial-resistant infections [version 1; peer review: 2 approved] F1000Research |
| title | Reinventing the antimicrobial pipeline in response to the global crisis of antimicrobial-resistant infections [version 1; peer review: 2 approved] |
| title_full | Reinventing the antimicrobial pipeline in response to the global crisis of antimicrobial-resistant infections [version 1; peer review: 2 approved] |
| title_fullStr | Reinventing the antimicrobial pipeline in response to the global crisis of antimicrobial-resistant infections [version 1; peer review: 2 approved] |
| title_full_unstemmed | Reinventing the antimicrobial pipeline in response to the global crisis of antimicrobial-resistant infections [version 1; peer review: 2 approved] |
| title_short | Reinventing the antimicrobial pipeline in response to the global crisis of antimicrobial-resistant infections [version 1; peer review: 2 approved] |
| title_sort | reinventing the antimicrobial pipeline in response to the global crisis of antimicrobial resistant infections version 1 peer review 2 approved |
| url | https://f1000research.com/articles/8-238/v1 |
| work_keys_str_mv | AT andrewcsinger reinventingtheantimicrobialpipelineinresponsetotheglobalcrisisofantimicrobialresistantinfectionsversion1peerreview2approved AT claaskirchhelle reinventingtheantimicrobialpipelineinresponsetotheglobalcrisisofantimicrobialresistantinfectionsversion1peerreview2approved AT adamproberts reinventingtheantimicrobialpipelineinresponsetotheglobalcrisisofantimicrobialresistantinfectionsversion1peerreview2approved |